GE Healthcare, a global provider of medical technologies and pharmaceuticals has agreed to pay $30 million to settle a False Claims Act whistleblower case alleging the company provided false information in connection with its distribution of the radiopharmaceutical agent Myoview to the federal Medicare program. The drug is used by health care providers in cardiology to perform nuclear stress tests. The whistleblowers said that the company orchestrated a scheme in which Myoview was improperly diluted in order to maximize trhe number of doses available per vial. This lead to an increased number of patient-ready doses and inflated Medicare reimbursements. Under the settlement, the whistleblowers will receive $5,100,000 as his reward for blowing the whislte. Costs and attorneys fees will also be paid.